US › Healthcare

Harvard Bioscience Inc (HBIO)

US · Healthcare · Medical Instruments & Supplies

$6.310.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$20.8M
Revenue YoY
-4.7%
Net profit
$-3.4M
Profit YoY
+93.2%
EPS
$-0.77
EPS estimate
$-0.95
Net margin
-16.5%

EPS came in at -0.77 against a street estimate of -0.95 — a beat of 18.9%.

Key statistics

Market cap
$27.5M
Forward P/E
15.1
P/B
2.74
Book value
$2.23
EPS (TTM)
$-2.15
52-week high
$9.40
52-week low
$3.75
50-day MA
$6.08
200-day MA
$5.93
Beta
1.50

Analyst view

Analysts rate Harvard Bioscience Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders
9.48%
Institutions
41.46%

Largest institutional holders

FundStake
Weber Capital Management LLC7.10%
Acadian Asset Management LLC3.98%
Vanguard Capital Management, LLC3.62%
Corsair Capital Management LLC2.77%
Meros Investment Management, LP2.63%
NANO CAP NEW MILLENNIUM GROWTH FUND L P2.61%
Two Sigma Investments LLC2.53%
Renaissance Technologies Corp2.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Harvard Bioscience Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.